Biopharmaceutical Facility in Boulder Changes Hands
AGC Biologics has purchased a state-of-the-art commercial biopharmaceutical facility in Boulder. The facility, formerly owned by London-based pharmaceutical giant AstraZeneca, will provide AGC Biologics with additional commercial-scale manufacturing capacity for its biopharmaceutical CDMO business when it enters operation in April 2021, more than 18 months sooner than a new-build facility. According to public records, the
Biopharmaceutical Facility in Boulder Changes Hands Read More »











